These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 12324628)

  • 21. Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis.
    Armstrong DK; Spriggs D; Levin J; Poulin R; Lane S
    Oncologist; 2005 Oct; 10(9):686-94. PubMed ID: 16249347
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer.
    Vergote I; Schilder RJ; Pippitt CH; Wong S; Gordon AN; Scudder S; Kridelka F; Dirix L; Leach JW; Ananda S; Nanayakkara N; Melara R; Bass MB; Litten J; Adewoye H; Wenham RM
    Gynecol Oncol; 2014 Oct; 135(1):25-33. PubMed ID: 25019569
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Haematological evaluation of weekly therapy with topotecan for the treatment of recurrent ovarian cancer resistant to platinum-based therapy.
    Largillier R; Valenza B; Ferrero JM; Novo C; Creisson A; Lesbats G; Mari V; Hebert C; Chamorey E
    Oncology; 2007; 73(3-4):177-84. PubMed ID: 18418010
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of salvage chemotherapy with topotecan and cisplatin in patients with paclitaxel- and platinum-resistant recurrent ovarian or primary peritoneal cancer: a phase II pilot study.
    Ghamande SA; Piver MS
    J Surg Oncol; 1999 Nov; 72(3):162-6. PubMed ID: 10562363
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma.
    Rose PG; Gordon NH; Fusco N; Fluellen L; Rodriguez M; Ingalls ST; Hoppel CL
    Gynecol Oncol; 2000 Aug; 78(2):228-34. PubMed ID: 10926808
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Weekly topotecan for recurrent ovarian, fallopian tube and primary peritoneal carcinoma: tolerability and efficacy study--the Israeli experience.
    Safra T; Berman T; Yachnin A; Bruchim I; Meirovitz M; Barak F; Atlas I; Levy T; Rosengarten OS
    Int J Gynecol Cancer; 2013 Mar; 23(3):475-80. PubMed ID: 23435437
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer.
    Clarke-Pearson DL; Van Le L; Iveson T; Whitney CW; Hanjani P; Kristensen G; Malfetano JH; Beckman RA; Ross GA; Lane SR; DeWitte MH; Fields SZ
    J Clin Oncol; 2001 Oct; 19(19):3967-75. PubMed ID: 11579118
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer.
    Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
    Gynecol Oncol; 2000 Oct; 79(1):116-9. PubMed ID: 11006042
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Review of the use of topotecan in ovarian carcinoma.
    Ahmad T; Gore M
    Expert Opin Pharmacother; 2004 Nov; 5(11):2333-40. PubMed ID: 15500380
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.
    ten Bokkel Huinink W; Gore M; Carmichael J; Gordon A; Malfetano J; Hudson I; Broom C; Scarabelli C; Davidson N; Spanczynski M; Bolis G; Malmström H; Coleman R; Fields SC; Heron JF
    J Clin Oncol; 1997 Jun; 15(6):2183-93. PubMed ID: 9196130
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical evidence for topotecan-paclitaxel non--cross-resistance in ovarian cancer.
    Gore M; ten Bokkel Huinink W; Carmichael J; Gordon A; Davidson N; Coleman R; Spaczynski M; Héron JF; Bolis G; Malmström H; Malfetano J; Scarabelli C; Vennin P; Ross G; Fields SZ
    J Clin Oncol; 2001 Apr; 19(7):1893-900. PubMed ID: 11283120
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and tolerability of lower-dose topotecan in recurrent ovarian cancer: a retrospective case review.
    Mitchell SK; Carson LF; Judson P; Downs LS
    Int J Gynecol Cancer; 2005; 15(5):793-8. PubMed ID: 16174226
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How should we manage patients with "platinum-sensitive" recurrent ovarian cancer?
    Ledermann JA; Wheeler S
    Cancer Invest; 2004; 22 Suppl 2():2-10. PubMed ID: 15573740
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: A Gynecologic Oncology Group trial.
    Markman M; Blessing JA; DeGeest K; Morgan M; Look KY; Herzog TJ; Rose PG
    Gynecol Oncol; 1999 Dec; 75(3):444-6. PubMed ID: 10600304
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer.
    Rodriguez M; Rose PG
    Gynecol Oncol; 2001 Nov; 83(2):257-62. PubMed ID: 11606080
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Topotecan in heavily pretreated patients with recurrent ovarian, peritoneal, and fallopian tube carcinoma.
    Piura B; Rabinovich A
    Int J Gynecol Cancer; 2005; 15(4):612-7. PubMed ID: 16014114
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study.
    McGuire WP; Blessing JA; Bookman MA; Lentz SS; Dunton CJ
    J Clin Oncol; 2000 Mar; 18(5):1062-7. PubMed ID: 10694558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimal sequencing in the treatment of recurrent ovarian cancer.
    Spriggs D
    Gynecol Oncol; 2003 Sep; 90(3 Pt 2):S39-44. PubMed ID: 13129495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.